Skip to main content
SpringerLink
Log in

Improved high-performance liquid chromatography assay of doxorubicin: Detection of circulating aglycones in human plasma and comparison with thin-layer chromatography

  • Original Articles
  • HPLC and TLC of Doxorubicin
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

We compared doxorubicin and metabolite pharmacokinetic data obtained from thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC) assay of plasma samples from six patients who had been treated with doxorubicin. Duplicate 1-ml samples were extracted with chloroform: isopropanol (1:1) and assayed using a sensitive HPLC system incorporating a dual pump gradient with tetrahydrofuran as the mobile phase and fluorescence detection. Duplicate 1-ml samples from the same specimens were assayed using a modification of a previously described TLC assay. Areas under the curve for doxorubicin by HPLC (3.36±2.30 μM · h) and TLC (4.16±2.50 μM · h) were not significantly different (P=0.5). Terminal half-life of doxorubicin by HPLC (28.0±6.98 h) and TLC (23.2±7.8) (P=0.29) and the calculated total-body clearances by HPLC (0.55±0.29 l/min) and TLC (0.45±0.23) (P=0.55) were not significantly different. Areas under the curve for doxorubicinol by HPLC (2.75±1.4 μM · h) and TLC (2.53±7.1 μM · h) (P=0.73) showed no significant differences. HPLC detected a mixed 7-deoxydoxorubicinol aglycone-doxorubicin aglycone peak, 7-deoxydoxorubicin aglycone, and two nonpolar, unidentified metabolites. TLC detected the following aglycone metabolites: doxorubicin aglycone, doxorubicinol aglycone, 7-deoxydoxorubicinol aglycone, an unidentified polar metabolite, and several unidentified nonpolar metabolites. From these data we conclude that HPLC and TLC detect concentrations of doxorubicin and doxorubicinol from human plasma equally well to concentrations of 7.0 nM (4 pmol injected doxorubicin). Aglycones do circulate in human plasma at concentrations above the detection limits of both assays. Doxorubicinol aglycone, which is detected by TLC but not by HPLC, may be formed from artifactual breakdown of doxorubicinol during TLC development. Unidentified nonpolar compounds seen on HPLC and TLC may represent further doxorubicin metabolism than previously described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andrews PA, Brenner DE, Chou FTE, Kubo H, Bachur NR (1980) Facile and definitive determination of human adriamycin and daunorubicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos 8: 152

    Google Scholar 

  2. Averbuch SD, Finkelstein TT, Fandrick SE, Reich SD (1981) Anthracycline assay by high-pressure liquid chromatography. J Pharm Sci 70: 265

    Google Scholar 

  3. Bachur NR, Moore AL, Bernstein JG, Liu A (1970) Tissue distribution and disposition of daunomycin (NSC-82151) in mice: fluorometric and isotopic methods. Cancer Chemother Rep 54: 89

    Google Scholar 

  4. Baurain R, Deprez-DeCampencer D, Trouet A (1979) Rapid determination of doxorubicin and its fluorescent metabolites by high-pressure liquid chromatography. Anal Biochem 94: 112

    Google Scholar 

  5. Benjamin RS, Riggs CE, Bachur NR (1973) Pharmacokinetics of and metabolism of adriamycin in man. Clin Pharmacol Ther 14: 592

    Google Scholar 

  6. Benjamin RS, Riggs CE, Bachur NR (1977) Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37: 1416

    Google Scholar 

  7. Blum RH (1975) An overview of studies with adriamycin in the United States. Cancer Chemother Rep 6: 247

    Google Scholar 

  8. Eksborg S (1978) Reversed-phase liquid chromatography of adriamycin and daunorubicin and their hydroxyl metabolites adriamycinol and daunorubicinol. J Chromatogr 149: 225

    Google Scholar 

  9. Eksborg S, Ehrsson H (1978) Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients. J Chromatogr 153: 211

    Google Scholar 

  10. Glode LM, Israel M, Pegg WJ, Wilkinson PM (1977) Hepatobiliary metabolism and excretion of adriamycin in man. Br J Clin Pharmacol 4: 639

    Google Scholar 

  11. Hulhoven R, Desager JP (1976) Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography. J Chromatogr 125: 369

    Google Scholar 

  12. Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1978) Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. J Liquid Chromatogr 1: 795

    Google Scholar 

  13. Knott GD (1979) MLAB-A mathematical modeling tool. Comput Programs Biomed 10: 271

    Google Scholar 

  14. Peters JH, Murray JF (1979) Determination of adriamycin and aclacinomycin A in plasma by high pressure liquid chromatography and spectrophotofluorometry. J Liquid Chromatogr 2: 45

    Google Scholar 

  15. Pierce RN, Jatlow PI (1979) Measurement of adriamycin (doxorubicin) and its metabolites in human plasma using reversed phase high performance liquid chromatography and fluorescence detection. J Chromatogr 164: 471

    Google Scholar 

  16. Quattrone AJ, Ranney DF (1980) Simplified toxicologic monitoring of adriamycin, its major metabolites and nogalamycin by reverse-phase high pressure liquid chromatography. I. Analytical techniques for isolated human plasma. J Anal Toxicol 4: 12

    Google Scholar 

  17. Takakashi S, Bachur NR (1976) Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab Dispos 4: 79

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Medicine, Vanderbilt University, 37232, Nashville, TN, USA

    Dean E. Brenner, Sherri Galloway, John Cooper, Richard Noone & Kenneth R. Hande

  2. Nashville Veterans Administration Medical Center, 37203, Nashville, TN, USA

    Dean E. Brenner, Sherri Galloway, John Cooper, Richard Noone & Kenneth R. Hande

Authors
  1. Dean E. Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sherri Galloway
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Noone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth R. Hande
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brenner, D.E., Galloway, S., Cooper, J. et al. Improved high-performance liquid chromatography assay of doxorubicin: Detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. Cancer Chemother. Pharmacol. 14, 139–145 (1985). https://doi.org/10.1007/BF00434353

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00434353

Keywords

Search

Navigation